Form 4: Teva Pharmaceutical Executive Eric A. Hughes Executes Stock Sale Under 10b5-1 Plan

Eric A. Hughes, Executive Vice President at Teva Pharmaceutical Industries, sold shares of Teva stock on March 4th and 5th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Eric A. Hughes, an Executive Vice President at Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
• On March 4, 2025, Hughes exercised restricted share units, acquiring 23,251 ordinary shares.
• Also on March 4, 2025, Hughes sold 15,174 ordinary shares at an average price of $15.7346.
• On March 5, 2025, Hughes sold an additional 8,077 ordinary shares at an average price of $15.9132.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following these transactions, Hughes directly owns 0 ordinary shares.
• Hughes also owns 69,754 restricted share units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Executive stock sales are common and often pre-planned, especially in the pharmaceutical industry where compensation packages frequently include stock options and restricted share units.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options and restricted share units, aligning executive interests with shareholder value.
• Companies like Pfizer, Johnson & Johnson, and Merck also utilize similar compensation structures.
• The vesting schedules and trading plans are generally in line with industry norms to prevent insider trading and ensure transparency.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• However, given the pre-planned nature of the sales, the impact is likely to be minimal.

Key Dates